Fagron was founded in Rotterdam (the Netherlands) in 1990 by Ger van Jeveren, the current CEO
of the Fagron Group. Through a continuous focus on innovation, quality and solution-oriented thinking, Ger van Jeveren brought market leadership in pharmaceutical compounding to Fagron in the Netherlands in just 7 years.
Ger van Jeveren continued to direct further development and international growth, with the result that Fagron is currently the global market leader and active in 30 countries in Europe, the Americas, Africa, the Middle East, Asia, and the Pacific. Fagron products are sold to 200,000 customers in over 55 countries around the world.
Market leadership provides major competitive advantages, such as the central procurement of raw materials, optimal utilisation of production facilities, and the international roll-out of successful and innovative products and concepts. With over 1,300 employees, Fagron generated a turnover of
US$ 400 million in 2012.
Fagron intends to further reinforce its worldwide market leadership based on an active buy and-build strategy, starting up greenfields and robust organic growth
Fagron mission and strategy
Fagron’s strategy is focused on the optimisation and innovation of pharmaceutical compounding with the aim of widening the therapeutic scope of the prescriber to enable tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist and improves the patient’s quality of life.
Fagron, Inc. - USA
Fagron, Inc., headquartered in St. Paul, Minnesota, continues an excellent history of employee loyalty. Our staff remains intact in both our Minnesota and Arizona facilities, as we transition into a global entity. Ger van Jereven, CEO, believes pharmacists are integral to our companies, especially in International Quality Assurance and in the Innovation and Marketing areas. Our team includes pharmacists, certified pharmacy technicians, a PhD chemist, biologists, microbiologists, and a physicist, all working full time to provide materials, equipment, and professional technical assistance to compounders. We believe your success will contribute to our success.
We are increasing the size of our staff and we have expanded and streamlined our physical plant. Thank you to our customers for your ongoing support during our transition. We will continue our long tradition of responding to you, our customer, as you respond to patients’ needs. Fagron continues to be focused on optimizing and innovating for pharmacy compounding and to widen the scope and effectiveness of the prescriber and pharmacist. Fagron’s Innovation Department includes more than 150 pharmacists world-wide dedicated to developing and providing new and better ways to assist pharmacists as they provide best quality of life to their patients.
Fagron, Inc. has continued to grow through the years because of its innovation and ability to bring new products to the U.S. compounding market. One of Fagron’s strengths is in offering new bases and vehicles with the idea of varying approaches to providing medication and pharmaceutical elegance to compounded preparations. Pentravan and Pentravan Plus offer proven transdermal penetration. Phytobase , a natural cream base, addresses special needs for some patients. Versatile is our newest cream base that will accept up to 43% of Active Pharmaceutical Ingredients (APIs). The SyrSpend family of suspending vehicles provides a pleasant tasting means of customizing medication strengths and helping with patient compliance. Published stability studies have been done with various APIs to justify value. Our Espumil foaming vehicle and LolliBase hard-candy vehicle are also new and innovative.
Since 1980, Fagron, Inc. has been a US Food and Drug Administration-registered pharmaceutical manufacturer, adhering strictly to current Good Manufacturing Practices (cGMP). Bulk Pharmaceutical Ingredients (BPI) are purchased from reputable, registered, and validated manufacturers. Incoming BPIs are initially quarantined, then sampled and tested for identity, strength, quality, and purity in our Quality Control Laboratories, using methods as set forth in the applicable monographs of USP, NF, British Pharmacopoeia (BP), or European Pharmacopoeia (EP). Repackaging is performed in our climate-monitored facility, then retested by Quality Control (QC) and reviewed by Quality Assurance (QA) before release to the market.
Fagron underwrites continuing education for compounding pharmacists and technicians through the Compounding Matters Academy, with ACPE credit provided by the American College of Apothecaries (ACA). The classes focus on skills, techniques, and equipment used in modern extemporaneous compounding. Classes are held monthly in either Arizona or Minnesota. Participants gain hands-on experience compounding dose forms. They learn about references, regulatory issues, and marketing strategies for use as the practice grows. Aseptic compounding classes are also provided in conjunction with the ACA.
Fagron is always looking to the future and is a rotation site for 5th year PharmD students attending the University of Minnesota College of Pharmacy and North Dakota State University College of Pharmacy. These students gain an appreciation for “The Art of Compounding®,” as we benefit from their fresh insights.
No comments:
Post a Comment